I hope you're right
Like I said, there are a lot variables that remain to be revealed, but I'm comfortable with my analysis at this point. As they say, valuation is more art than science, particularly when it comes to high-growth, early-stage companies.
We're all in agreement that the company is in a sweet spot when it comes to end markets and the valuation multiples applied to those types of companies.